Group B Streptococcus ( GBS) is a conditional pathogenic bacteria related to late-term abortion, premature delivery, premature rupture of membranes, perinatal infection, neonatal sepsis and other diseases.Prevention and treatment guidelines by the US Centers for Disease Control and Prevention ( CDC) suggest that all the pregnant women at 35-37 gestational weeks should screen for GBS .The detection methods for GBS include microbiology , immunology, molecular biology, etc.The appropriate method should be chosen depending on circumstances .Penicillin is recommended for the preventive treatment of GBS , and the treatment for the insensitive should base on the antibiotic susceptibility results .No vaccine against GBS is currently available for clinical use .

Since recombinant human growth hormone (rhGH) was licensed for growth hormone deficiency(GHD) in 1985,it has been available in short stature associated with Turner syndrome (TS),being born small for gestational age,idiopathic short stature,chronic renal insufficiency in the last 20 years.The overall safety profile of rhGH continues to be favorable,but careful monitoring for the presence of certain conditions is important both during and after therapy.Reasonable indication,time of therapy and dosage are important to obtain the ideal result and save the expense.Besides,the efforts to improve rhGH therapy and increase compliance have also led to the investigation of extended-release rhGH and less invasive administration routes.Recent advances in the treatment of rhGH are reviewed in details.

It has been well established that interactions between CD40 and CD40L,expressed in a variety of cell types including platelets,vascular endothelial cells,and immune cells,are actively involved in the development of glomerulonephritis,lupus nephritis,and the other kidney disease caused by immunological and unimmunological factors,and that tubular cells expression of CD40 was correlated well with the degree of tubulointerstitial inflammation and injury.The development of therapeutic strategies specifically accommodating CD40/CD40L seem promising against renal glomerular disease.The paper reviews the new advances in this

Conotruncal anomaly is composed of a group of complex congenital heart diseases. Cardiac outflow tract (OFT) plays an essential role in the cardiac conotruncal development. Recently, transforming growth factor β/bone morphogenetic protein signaling pathway has become a research hotspot, which is recognized as a important regulation mechanism in many processes of the cardiac development, such as separation of OFT and maturation of septums. In this paper we describe the role of the signaling pathway and its effect on the development of cardiac OFT.

Objective:To further investigate the effects of three kinds of material on the level of aspartate aminotransferase (AST) and alkaline phosphatase (ALP) in gingival crevicular fluid (GCF). Methods:The anterior teeth and the premolar teeth of 30 patients were divided into three groups randomly for Co-Cr alloy PFM, Ti PFM and all ceramic crown. Before tooth preparation, 1, 3 and 6 months after cementation, GCF was collected at the same sites. The levels of AST and ALP were detected by automated chemical analyzer, and analyzed the variation between the pre-restoration and post-restoration. Results:Before tooth preparation and 1 month after cementation, all indexes showed no difference among three groups. The level of GCF, AST and ALP of Co-Cr alloy group showed conspicuous difference with Ti PFM and all ceramic crowns after 3 months and 6 months. However, the levels of GCF, AST and ALP of Ti PFM group showed no difference with all ceramic crowns. Conclusion:Co-Cr based PFM crowns which clinically accepted have lead to changes of the levels of GCF, AST and ALP. Co-Cr based PFM crowns have negative influences on periodontal tissue. The Ti PFM and all ceramic crown may affect periodontium less than the Co-Cr PFM in observation period of this study.

Objective:To prepare DHAQ-GM-CSF immunoliposomes and observe the cytotoxicity of HL60 cells treated with the immunoliposomes for providing the preclinical data for AML therapy. Methods:DHAQ liposomes were prepared by reverse-phase evaporation(REV),and GM-CSF was coupled to the DHAQ liposomes.The cytotoxicity of HL60 cells treated with the immunoliposomes was measured by tetrazolium microculture(MTT) celluar cytotoxicity test.The data of cellar untrastructure and apoptotic rate were collected by transmission electron microscopy,and flow cytometric analysis. Results:DHAQ-GM-CSF immunoliposomes had better effects on the cytotoxicity of HL60 cells than DHAQ liposomes and DHAQ.The cellar untrastructure was markly destroyed and many apoptotic bodies formed after the treatment. Conclusion:DHAQ-GM-CSF immunoliposomes are successfully prepared and verified,which have targeting cytotoxicity on HL60 cells.The study establishes the foundation for futher investigation.

ObjectiveTo discuss the clinical value of mechanical ventilation in treatment the children with critical hand foot and mouth disease (HFMD) complicated with neurogenic pulmonary edema.MethodsThe clinical manifestations,laboratorydata,treatment,and outcome of 35 children with critical HFMD complicated with neurogenic pulmonary edema were retrospectively analyzed.Results35 cases had fever,34 cases had skin rash,33 cases had limb jitter,30 cases were easily frightened,30 cases lack of energy,34 cases had respiratory rhythm changes,18 cases vomited foam,18 cases poured pink in nose and mouth,22 cases had disturbance of consciousness,8 cases had flaccid paralysis.There were 30 cases with bilateral pulmonary exudative lesions in Chest X-ray.35 children were given mechanical ventilation based on the comprehensive treatment,and 3 cases of lower limb mobility impairments,12 cases died of pulmonary hemorrhage within 24 hours of admission,the rest was released.ConclusionEarly mechanical ventilation based on the comprehensive treatment is an important measure of successful treatment in children with critical HFMD complicated with neurogenic pulmonary edema.

Objective To evaluate the effect of alpha-lipon and Chinese medicine on diabetic peripheral neuropathy.Methods Sixty patients with diabetic peripheral neuropathy were randomly divided into two groups.The treatment group were treated with alpha-lipon 600 mg/day by intravenous drip and 150 ml Chinese medicine twice daily for two weeks.The control group were treated with alpha-lipon 600 mg daily for two weeks.All patients were evaluated with TSS score and quantitative sensory tests before and after the treatment.Results There were significant differences on the conduction velocities of the tibial nerve((44.36 ±4.05) m/s vs (51.53 ± 4.76) rm/s ; t =9.6 ; P ＜ 0.01),the peroneal nerve ((43.87 ± 3.81) m/s vs (48.46 ±3.91) m/s;t =8.7;P＜0.01) and the sural nerve (42.31 ±5.05) m/s vs (47.76±5.06) m/s;t =7.9;P＜0.01) in the treatment group before and after treatment.For the control group,only significant differences on the conduction velocities of the tibial nerve ((44.78 ± 5.51) m/s vs.(46.18 ± 5.76) m/s ;t =3.5 ;P ＜ 0.01) and the sural nerve (40.76 ±5.86) m/s vs.(43.71 ±5.91) m/s;t =4.2;P ＜0.01) were observed before and after treatment.There was no sigfinicant difference found on the conduction velocities of the peroneal nerve ((44.48 ± 5.21) m/s vs (44.02 ± 5.71) m/s; t =2.7 ; P ＞ 0.05).Compared with the control group,the treatment group had more significant improvement of the conduction velocities of the tibial nerve (t =6.1 ; P ＜0.01),the peroneal nerve(t =4.8 ;P ＜ 0.01) and the sural nerve (t =5.4 ; P ＜ 0.01) after treatment for two weeks.The effective rate was significantly higher in the treatment group than in the control group (80％ (24/31)vs 60％ (18/30) ;x2 =5.01 ;P ＜ 0.05).No patients had severe drug side reaction.Conclusion Treatment of alpha-lipon combined Chinese medicine on patients with diabetic peripheral neuropathy is safe and effective.

Several multi-gene assays have been developed to predict the risk of recurrence in patients with early-stage, estrogen receptor (ER) positive breast cancer. Among them, Oncotype DX 21-gene assay is widely applied among node-negative patients because of its unique prediction of therapeutic benefit. Although many retrospective stud-ies have proved its prognostic and predictive value in node-positive population, evidence from large prospective clinical trials remains insufficient. When combined with clinicopathological variables, the assay has been shown to impact adjuvant treatment decision making in a cost-effective manner. This article reviewed the available clinical evidence for the prognostic and predictive value, unique advantages, the effect on treatment decision making, cost-effectiveness and contradictories of 21-gene assay in early-stage luminal breast cancer patients.